Pharma giant regeneron to buy 23andme and their customers data for $ 256 m

Regeneron pharmaceutical maker announced on monday Will buy the genetic company testing 23 286 million $ 256 after an auction of failure.

Regeneron said that acquires 23andme’s genomic service and bank of the personal data of 15 million and genetics as part of the agreement. The Phant Phone Jigant said that two customer data to help the drug-and that will be “privacing, customer security.”

23DME Filed for the protection of failure in March After a data violation Exposed the private and genetic data of 7 million customer all over 2023. The stock’s stock price has also attached to the zero of the consumer’s consumer’s zero zero in the company test company. The Founder of 23rd and Chief Executive Anne Wojcicki has sized by the company after the company’s collapse.

After his / her federal court was appointed to the Sale Selling order, spilling the concerns that customer data shops could be sold to the adversarial nations oi non-ethical buyers. I am

Regeneron said in their statement that as the buyer called in the failure, “intend to respect” with the law of privacy of 23 saying of customers.

The failing court is set acquisition regeneron on 5 June 17. Regeneron said he has not purchased of Lemonids health